SCHEMBL5654426

SCHEMBL5654426

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccc(Cl)cc2)c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
NPSR1 Q6W5P4 1/20 0.47
CSF1R P07333 1/20 0.45
CYP1A2 P05177 1/20 0.45
HPGD P15428 1/20 0.45
XBP1 P17861 1/20 0.45
CYP2C19 P33261 1/20 0.45
DHODH Q02127 2/20 0.45
MAPT P10636 4/20 0.44
POLB P06746 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 1/20 0.42
GRM6 O15303 1/20 0.42
CHEK1 O14757 1/20 0.42
EGFR P00533 1/20 0.42
KDR P35968 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MDM2 Q00987 1/20 0.41
JUN P05412 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648531 0.96 ALDH1A1 (0.47) ALDH1A1NPSR1CSF1RCYP1A2HPGD
SCHEMBL5650136 0.93 MAPT (0.51) ALDH1A1NPSR1HPGDMAPTPOLB
SCHEMBL5650867 0.92 MAPT (0.47) ALDH1A1NPSR1CYP1A2HPGDCYP2C19
SCHEMBL5652595 0.91 MAPT (0.45) ALDH1A1HPGDMAPTPOLBMEN1
SCHEMBL5652764 0.91 MAPT (0.45) ALDH1A1HPGDMAPTPOLBMEN1
SCHEMBL5654915 0.90 MAPT (0.43) ALDH1A1HPGDMAPTPOLBMEN1
SCHEMBL5652293 0.90 MAPT (0.44) ALDH1A1NPSR1HPGDMAPTPOLB
SCHEMBL5647395 0.90 MAPT (0.50) ALDH1A1CYP1A2HPGDCYP2C19DHODH
SCHEMBL5652339 0.90 MAPT (0.44) ALDH1A1CYP1A2HPGDCYP2C19MAPT
SCHEMBL5651738 0.89 TRPM8 (0.48) ALDH1A1CSF1RCYP1A2HPGDXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ALDH1A1 1498/4885NPSR1 715/4885CSF1R 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.